Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Kidney Dis ; 81(5): 564-574, 2023 05.
Artigo em Inglês | MEDLINE | ID: mdl-36470530

RESUMO

RATIONALE & OBJECTIVE: Sick day medication guidance (SDMG) involves withholding or adjusting specific medications in the setting of acute illnesses that could contribute to complications such as hypotension, acute kidney injury (AKI), or hypoglycemia. We sought to achieve consensus among clinical experts on recommendations for SDMG that could be studied in future intervention studies. STUDY DESIGN: A modified Delphi process following guidelines for conducting and reporting Delphi studies. SETTING & PARTICIPANTS: An international group of clinicians with expertise relevant to SDMG was recruited through purposive and snowball sampling. A scoping review of the literature was presented, followed by 3 sequential rounds of development, refinement, and voting on recommendations. Meetings were held virtually and structured to allow the participants to provide their input and rapidly prioritize and refine ideas. OUTCOME: Opinions of participants were measured as the percentage who agreed with each recommendation, whereas consensus was defined as >75% agreement. ANALYTICAL APPROACH: Quantitative data were summarized using counts and percentages. A qualitative content analysis was performed to capture the context of the discussion around recommendations and any additional considerations brought forward by participants. RESULTS: The final panel included 26 clinician participants from 4 countries and 10 clinical disciplines. Participants reached a consensus on 42 specific recommendations: 5 regarding the signs and symptoms accompanying volume depletion that should trigger SDMG; 6 regarding signs that should prompt urgent contact with a health care provider (including a reduced level of consciousness, severe vomiting, low blood pressure, presence of ketones, tachycardia, and fever); and 14 related to scenarios and strategies for patient self-management (including frequent glucose monitoring, checking ketones, fluid intake, and consumption of food to prevent hypoglycemia). There was consensus that renin-angiotensin system inhibitors, diuretics, nonsteroidal anti-inflammatory drugs, sodium/glucose cotransporter 2 inhibitors, and metformin should be temporarily stopped. Participants recommended that insulin, sulfonylureas, and meglitinides be held only if blood glucose was low and that basal and bolus insulin be increased by 10%-20% if blood glucose was elevated. There was consensus on 6 recommendations related to the resumption of medications within 24-48 hours of the resolution of symptoms and the presence of normal patterns of eating and drinking. LIMITATIONS: Participants were from high-income countries, predominantly Canada. Findings may not be generalizable to implementation in other settings. CONCLUSIONS: A multidisciplinary panel of clinicians reached a consensus on recommendations for SDMG in the presence of signs and symptoms of volume depletion, as well as self-management strategies and medication instructions in this setting. These recommendations may inform the design of future trials of SDMG strategies.


Assuntos
Doenças Cardiovasculares , Diabetes Mellitus , Hipoglicemia , Insulinas , Humanos , Doenças Cardiovasculares/tratamento farmacológico , Glicemia , Consenso , Automonitorização da Glicemia , Licença Médica , Diabetes Mellitus/tratamento farmacológico , Hipoglicemia/induzido quimicamente , Hipoglicemia/prevenção & controle , Hipovolemia , Rim , Técnica Delphi
2.
Health Expect ; 26(4): 1746-1756, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-37291977

RESUMO

INTRODUCTION: People with chronic medical conditions often take medications that improve long-term outcomes but which can be harmful during acute illness. Guidelines recommend that healthcare providers offer instructions to temporarily stop these medications when patients are sick (i.e., sick days). We describe the experiences of patients managing sick days and of healthcare providers providing sick day guidance to their patients. METHODS: We undertook a qualitative descriptive study. We purposively sampled patients and healthcare providers from across Canada. Adult patients were eligible if they took at least two medications for diabetes, heart disease, high blood pressure and/or kidney disease. Healthcare providers were eligible if they were practising in a community setting with at least 1 year of experience. Data were collected using virtual focus groups and individual phone interviews conducted in English. Team members analyzed transcripts using conventional content analysis. RESULTS: We interviewed 48 participants (20 patients and 28 healthcare providers). Most patients were between 50 and 64 years of age and identified their health status as 'good'. Most healthcare providers were between 45 and 54 years of age and the majority practised as pharmacists in urban areas. We identified three overarching themes that summarize the experiences of patients and healthcare providers, largely suggesting a broad spectrum in approaches to managing sick days: Individualized Communication, Tailored Sick Day Practices, and Variation in Knowledge of Sick Day Practices and Relevant Resources. CONCLUSION: It is important to understand the perspectives of both patients and healthcare providers with respect to the management of sick days. This understanding can be used to improve care and outcomes for people living with chronic conditions during sick days. PATIENT OR PUBLIC CONTRIBUTION: Two patient partners were involved from proposal development to the dissemination of our findings, including manuscript development. Both patient partners took part in team meetings and contributed to team decision-making. Patient partners also participated in data analysis by reviewing codes and theme development. Furthermore, patients living with various chronic conditions and healthcare providers participated in focus groups and individual interviews.


Assuntos
Pessoal de Saúde , Licença Médica , Adulto , Humanos , Pesquisa Qualitativa , Farmacêuticos , Doença Crônica
3.
BMC Med Inform Decis Mak ; 20(1): 287, 2020 11 04.
Artigo em Inglês | MEDLINE | ID: mdl-33148237

RESUMO

BACKGROUND: Acute kidney injury (AKI) is common in hospitalized patients and is associated with poor patient outcomes and high costs of care. The implementation of clinical decision support tools within electronic medical record (EMR) could improve AKI care and outcomes. While clinical decision support tools have the potential to enhance recognition and management of AKI, there is limited description in the literature of how these tools were developed and whether they meet end-user expectations. METHODS: We developed and evaluated the content, acceptability, and usability of electronic clinical decision support tools for AKI care. Multi-component tools were developed within a hospital EMR (Sunrise Clinical Manager™, Allscripts Healthcare Solutions Inc.) currently deployed in Calgary, Alberta, and included: AKI stage alerts, AKI adverse medication warnings, AKI clinical summary dashboard, and an AKI order set. The clinical decision support was developed for use by multiple healthcare providers at the time and point of care on general medical and surgical units. Functional and usability testing for the alerts and clinical summary dashboard was conducted via in-person evaluation sessions, interviews, and surveys of care providers. Formal user acceptance testing with clinical end-users, including physicians and nursing staff, was conducted to evaluate the AKI order set. RESULTS: Considerations for appropriate deployment of both non-disruptive and interruptive functions was important to gain acceptability by clinicians. Functional testing and usability surveys for the alerts and clinical summary dashboard indicated that the tools were operating as desired and 74% (17/23) of surveyed healthcare providers reported that these tools were easy to use and could be learned quickly. Over three-quarters of providers (18/23) reported that they would utilize the tools in their practice. Three-quarters of the participants (13/17) in user acceptance testing agreed that recommendations within the order set were useful. Overall, 88% (15/17) believed that the order set would improve the care and management of AKI patients. CONCLUSIONS: Development and testing of EMR-based decision support tools for AKI with clinicians led to high acceptance by clinical end-users. Subsequent implementation within clinical environments will require end-user education and engagement in system-level initiatives to use the tools to improve care.


Assuntos
Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/terapia , Sistemas de Apoio a Decisões Clínicas , Registros Eletrônicos de Saúde , Alberta , Feminino , Hospitais , Humanos , Masculino
5.
Can J Kidney Health Dis ; 11: 20543581241236419, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38495365

RESUMO

Background: Acute kidney injury (AKI) is a common complication among hospitalized patients with long-term implications including chronic kidney disease (CKD). Although models are available to predict the risk of advanced CKD after AKI, there is limited evidence regarding follow-up for patients with AKI after hospital discharge, resulting in variable follow-up care. A risk-stratified follow-up approach may improve appropriateness and efficiency of management for CKD among patients at risk of declining kidney function following AKI. Objective: The objective was to compare and evaluate the use of a risk-stratified approach to follow-up care vs usual care for patients with AKI after hospital discharge. Design: This study was a pragmatic randomized controlled trial. Setting: This study was conducted in 2 large urban hospitals in Alberta, Canada. Patients: Hospitalized patients with AKI (KDIGO stage 2 or 3) not previously under the care of a nephrologist, expected to survive greater than 90 days being discharged home. Measurements: We will evaluate whether guideline-recommended CKD care processes are initiated within 90 days, including statin use, angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) use in those with proteinuria or diabetes, and nephrologist follow-up if sustained eGFR <30 mL/min/1.73 m2. We will also assess the feasibility of recruitment and the proportion of patients completing the recommended blood and urine tests at 90 days. Methods: Patients with AKI will be enrolled and randomized near the time of hospital discharge. In the intervention group, low risk patients will receive information regarding AKI, medium risk patients will additionally receive follow-up guidance sent to their primary care physician, and high-risk patients will additionally receive follow-up with a nephrologist. Participants in the intervention and usual care group will receive a requisition for urine testing and bloodwork at 90 days following hospital discharge. Telephone follow-up will be conducted for all study participants at 90 days and 1 year after hospital discharge. Bivariate tests of association will be conducted to evaluate group differences at the follow-up time points. Limitations: We expect there may be challenges with recruitment due to the significant co-existence of comorbidity in this population. Conclusions: If the trial shows a positive effect on these processes for kidney care, it will inform larger-scale trial to determine whether this intervention reduces the incidence of long-term clinical adverse events, including CKD progression, cardiovascular events, and mortality following hospitalization with AKI.


Contexte: L'insuffisance rénale aiguë (IRA) est une complication fréquente chez les patients hospitalisés qui peut avoir des conséquences à long terme, notamment l'insuffisance rénale chronique (IRC). Bien que des modèles de prédiction du risque d'IRC avancée après un épisode d'IRA soient disponibles, peu de données existent sur le suivi des patients atteints d'IRA après leur sortie de l'hôpital, ce qui se traduit par une variabilité dans les soins de suivi. Une approche de suivi stratifiée selon le risque d'IRC peut améliorer la qualité et l'efficacité de la prise en charge de l'IRC chez les patients dont la fonction rénale risque de se détériorer après un épisode d'IRA. Objectifs: Évaluer l'utilisation d'une approche de suivi post-hospitalisation stratifiée selon le risque d'IRC chez les patients atteints d'IRA et la comparer aux soins habituels. Conception: Essai contrôlé randomisé pragmatique. Cadre: Deux grands hôpitaux urbains en Alberta (Canada). Sujets: Patients hospitalisés avec une IRA (stade KDIGO 2 ou 3) qui n'étaient pas suivis auparavant par un néphrologue et dont on prévoyait la survie au-delà de 90 jours après leur sortie de l'hôpital. Mesures: Nous évaluerons si, dans les 90 jours suivant le congé, les soins d'IRC habituels recommandés par les lignes directrices seront amorcés, c'est-à-dire l'utilisation de statines, l'utilisation d'IECA/ARA chez les patients souffrant de protéinurie ou de diabète, et le suivi avec un néphrologue pour les patients avec un DFGe inférieur à 30 ml/min/1,73 m2 de façon soutenue. Nous évaluerons également la faisabilité du recrutement et la proportion de patients qui auront effectué les analyses sanguines et urinaires recommandées à 90 jours. Méthodologie: Les patients atteints d'IRA seront recrutés et randomisés au moment de leur sortie de l'hôpital. Dans le groupe d'intervention, les patients présentant un faible risque d'évolution recevront de l'information sur l'IRA, les patients présentant un risque moyennement élevé recevront en plus des conseils de suivi envoyés à leur médecin de premier recours, et les patients présentant un risque élevé feront également l'objet d'un suivi avec un néphrologue. Les participants des groupes intervention et soins habituels recevront une requête pour des analyses de sang et d'urine 90 jours après la sortie de l'hôpital. Un suivi téléphonique sera effectué auprès de tous les participants à l'étude 90 jours et un an après la sortie de l'hôpital. Des tests d'association bivariés seront effectués pour évaluer les différences entre les groupes aux points temporels de suivi. Limites: Nous nous attendons à ce que le recrutement soit difficile, considérant l'importance des comorbidités dans cette population. Conclusion: Si l'essai montre un effet positif sur ces processus de soins rénaux, il informera un essai à plus grande échelle visant à déterminer si cette intervention réduit l'incidence des événements cliniques indésirables à long terme, notamment la progression de l'IRC, les événements cardiovasculaires et la mortalité après une hospitalisation avec épisode d'IRA.

6.
Can J Diabetes ; 48(4): 259-268.e4, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38395301

RESUMO

OBJECTIVES: Our aim in this work was to 1) explore barriers and enablers to patient and health-care provider (HCP) behaviours related to sick-day medication guidance (SDMG), 2) identify theory-informed strategies to advise SDMG intervention design, and 3) obtain perspectives on an eHealth tool for this purpose. METHODS: A qualitative descriptive study using qualitative conventional content analysis was undertaken. Interviews and focus groups were held with patients and HCPs from January 2021 to April 2022. Data were analyzed using the Behaviour Change Wheel and Theoretical Domains Framework to inform intervention design. RESULTS: Forty-eight people (20 patients, 13 pharmacists, 12 family physicians, and 3 nurse practitioners) participated in this study. Three interventions were designed to address the identified barriers and enablers: 1) prescriptions provided by a community-based care provider, 2) pharmacists adding a label to at-risk medications, and 3) built-in prompts for prescribing and dispensing software. Most participants accepted the concept of an eHealth tool and identified pharmacists as the ideal point-of-care provider. Challenges for an eHealth tool were raised, including credibility, privacy of data, medical liability, clinician remuneration and workload impact, and equitable access to use of the tool. CONCLUSIONS: Patients and HCPs endorsed non-technology and eHealth innovations as strategies to aid in the delivery of SDMG. These findings can guide the design of future theory-informed SDMG interventions.


Assuntos
Doenças Cardiovasculares , Humanos , Feminino , Masculino , Pessoa de Meia-Idade , Pesquisa Qualitativa , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/terapia , Diabetes Mellitus/psicologia , Telemedicina , Idoso , Adulto , Nefropatias/terapia , Grupos Focais , Pessoal de Saúde/psicologia
7.
Kidney360 ; 2024 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-39146029

RESUMO

INTRODUCTION: High-quality clinical trials are needed to establish the efficacy and safety of novel therapies for acute kidney injury (AKI) prevention. In this consensus workshop, we identified patient and caregiver priorities for recruitment, intervention delivery, and outcomes of a clinical trial of cilastatin to prevent nephrotoxic AKI. METHODS: We included adults with lived experience of AKI, chronic kidney disease, or risk factors for AKI (e.g., critical care hospitalization), and their caregivers. Using a modified nominal group technique approach, we conducted a series of hybrid in-person/virtual discussions covering 3 clinical trial topic areas: (1) consent and recruitment; (2) intervention delivery; and (3) trial outcomes. Participants voted on their top preferences in each topic area, and discussion transcripts were analyzed inductively using conventional content analysis. RESULTS: Thirteen individuals (11 patients, 2 caregivers) participated in the workshop. For consent and recruitment, participants prioritized technology enabled pre-screening and involvement of family members in the consent process. For intervention delivery, participants prioritized measures to facilitate ease of intervention administration and return visits. For trial outcomes, participants identified kidney-related and other clinical outcomes (e.g., AKI, chronic kidney disease, cardiovascular events) as top priorities. Analysis of transcripts provided insight into care team and family involvement in trial-related decisions, implications of allocation to a placebo arm, and impact of participants' experiences of AKI and critical illness. CONCLUSION: Findings from our workshop will directly inform development of a clinical trial protocol of cilastatin for nephrotoxic AKI prevention and can assist others in patient-centered approaches to AKI trial design.

8.
J Patient Rep Outcomes ; 8(1): 102, 2024 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-39196484

RESUMO

BACKGROUND: Coronary artery disease (CAD) confers increased risks of premature mortality, non-fatal morbidity, and significant impairment in functional status and health-related quality of life. Routine administration of electronic patient-reported outcome measures (PROMs) and its real time delivery to care providers is known to have the potential to inform routine cardiac care and to improve quality of care and patient outcomes. This study describes a user-centered development and evaluation of the Alberta Provincial Project for Outcomes Assessment (APPROACH) electronic Patient Reported Outcomes Measurement (e-PROM) system. This e-PROM system is an electronic system for the administration of PROMs to patients with CAD and the delivery of the summarized information to their care providers to facilitate patient-physician communication and shared decision-making. This electronic platform was designed to be accessible via web-based and hand-held devices. Heuristic and user acceptance evaluation were conducted with patients and attending care providers. RESULTS: The APPROACH e-PROM system was co-developed with patients and care providers, research investigators, informaticians and information technology experts. Five PROMs were selected for inclusion in the online platform after consultations with patient partners, care providers, and PROMs experts: the Seattle Angina Questionnaire, Patient Health Questionnaire, EuroQOL, and Medical Outcomes Study Social Support Survey, and Self-Care of Coronary Heart Disease Inventory. The heuristic evaluation was completed by four design experts who examined the usability of the prototype interfaces. User acceptance testing was completed with 13 patients and 10 cardiologists who evaluated prototype user interfaces of the e-PROM system. CONCLUSION: Both patients and physicians found the APPROACH e-PROM system to be easy to use, understandable, and acceptable. The APPROACH e-PROM system provides a user-informed electronic platform designed to incorporate PROMs into the delivery of individualized cardiac care for persons with CAD.


Assuntos
Doença da Artéria Coronariana , Medidas de Resultados Relatados pelo Paciente , Humanos , Doença da Artéria Coronariana/terapia , Feminino , Masculino , Alberta , Qualidade de Vida , Pessoa de Meia-Idade , Design Centrado no Usuário , Idoso , Internet , Relações Médico-Paciente
9.
Can J Kidney Health Dis ; 10: 20543581231206127, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37867500

RESUMO

Purpose of program: Different models exist to guide successful implementation of electronic health tools into clinical practice. The Contrast Reducing Injury Sustained by Kidneys (Contrast RISK) initiative introduced an electronic decision support tool with physician audit and feedback into all of the cardiac catheterization facilities in Alberta, Canada, with the goal of preventing contrast-associated acute kidney injury (CA-AKI) following coronary angiography and intervention. This report describes the change management approaches used by the initiative and end-user's feedback on these processes. Sources of information and methods: The Canada Health Infoway Change Management model was used to address 6 activities relevant to project implementation: governance and leadership, stakeholder engagement, communications, workflow analysis and integration, training and education, and monitoring and evaluation. Health care providers and invasive cardiologists from all sites completed preimplementation, usability, and postimplementation surveys to assess integration and change success. Key findings: Prior to implementation, 67% of health providers were less than satisfied with processes to determine appropriate contrast dye volumes, 47% were less than satisfied with processes for administering adequate intravenous fluids, and 68% were less than satisfied with processes to ensure follow-up of high-risk patients. 48% of invasive cardiologists were less than satisfied with preprocedural identification of patients at risk of acute kidney injury (AKI). Following implementation, there were significant increases among health providers in the odds of satisfaction with processes for identifying those at high risk of AKI (odds ratio [OR] 3.01, 95% confidence interval [CI] 1.36-6.66, P = .007), quantifying the appropriate level of contrast dye for each patient (OR 6.98, 95% CI 3.06-15.91, P < .001), determining the optimal amount of IV fluid for each patient (OR 1.86, 95% CI 0.88-3.91, P = .102), and following up of kidney function of high risk patients (OR 5.49, 95%CI 2.45-12.30, P < .001). There were also significant increases among physicians in the odds of satisfaction with processes for identifying those at high risk of AKI (OR 19.53, 95% CI 3.21-118.76, P = .001), quantifying the appropriate level of contrast dye for each patient (OR 26.35, 95% CI 4.28-162.27, P < .001), and for following-up kidney function of high-risk patients (OR 7.72, 95% CI 1.62-36.84.30, P = .010). Eighty-nine percent of staff perceived the initiative as being successful in changing clinical practices to reduce the risk of CA-AKI. Physicians uniformly agreed that the system was well-integrated into existing workflows, while 42% of health providers also agreed. Implications: The Canada Health Infoway Change Management model was an effective framework for guiding implementation of an electronic decision support tool and audit and feedback intervention to improve processes for AKI prevention within cardiac catheterization units.


Objectif du program: Il existe différents modèles pour guider la mise en œuvre efficace d'outils électroniques dans la pratique clinique. L'initiative Contrast RISK (Contrast Reducing Injury Sustained by Kidneys) a permis d'introduire un outil électronique d'aide à la décision avec surveillance par le médecin et rétroaction dans tous les établissements de l'Alberta (Canada) pratiquant le cathétérisme cardiaque, dans le but de prévenir les insuffisances rénales aiguës associées aux produits de contraste (IRA-PC) après une coronarographie et une intervention. Le présent rapport décrit les approches de gestion du changement utilisées dans le cadre de l'initiative, ainsi que les commentaires des utilisateurs sur ces processus. Sources de l'information et méthodologie: Le modèle de gestion du changement d'Inforoute Santé du Canada a été employé pour aborder six activités pertinentes pour la mise en œuvre de projets: gouvernance et leadership, engagement des intervenants, communications, analyze du flux de travail et intégration, formation et éducation, surveillance et évaluation. Les prestataires de soins et les cardiologues spécialisés en interventions invasives de tous les sites ont répondu à un sondage avant, pendant et après la mise en œuvre afin d'évaluer le succès de l'intégration et du changement. Principaux résultats: Avant la mise en œuvre, 67% des prestataires de soins étaient insatisfaits des processus pour déterminer les volumes appropriés des produits de contraste, 47% étaient insatisfaits des processus pour administrer l'hydratation intraveineuse et 68% étaient insatisfaits des processus de surveillance des patients présentant un risque élevé. Près de la moitié (48%) des cardiologues spécialisés en interventions invasives étaient insatisfaits du processus d'identification préalable des patients présentant un risque élevé d'IRA. Après la mise en œuvre, on a observé une augmentation significative de la satisfaction des prestataires de soins à l'égard des processus pour identifier les patients présentant un risque élevé d'IRA (rapport de cote [RC]: 3,01; IC 95%: 1,36-6,66; P = .007), quantifier le niveau approprié de produit de contraste pour chaque patient (RC: 6,98; IC 95%: 3,06-15,91; P < .001), déterminer le volume optimal d'hydratation IV pour chaque patient (RC: 1,86, IC 95%: 0,88-3,91; P = .102) et surveiller la fonction rénale chez les patients présentant un risque élevé (RC: 5,49 IC 95%: 2,45-12,30; P < .001). On a également observé une augmentation significative de la satisfaction des médecins à l'égard des processus pour identifier les patients présentant un risque élevé d'IRA (RC: 19,53; IC 95%: 3,21-118,76; P = .001), quantifier le niveau approprié de produit de contraste pour chaque patient (RC: 26,35; IC 95%: 4,28-162,27; P < .001) et surveiller la fonction rénale des patients présentant un risque élevé (RC: 7,72; IC 95%: 1,62-36,84,30; P = .010). Une grande majorité du personnel (89%) était d'avis que l'initiative avait permis de changer les pratiques cliniques visant à réduire le risque d'IRA-PC. L'ensemble des médecins s'entendait pour dire que le système était bien intégré dans les flux de travail existants; 42% des prestataires de soins étaient également de cet avis. Conclusion: Le modèle de gestion du changement d'Inforoute Santé du Canada s'est avéré un cadre efficace pour guider la mise en œuvre d'un outil électronique d'aide à la décision et d'une intervention de surveillance et de rétroaction visant à améliorer les processus de prévention de l'IRA dans les unités de cathétérisme cardiaque.

10.
CJC Open ; 4(3): 271-281, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35386131

RESUMO

Background: Contrast-associated acute kidney injury (CA-AKI) is a potentially preventable complication of coronary angiography and intervention. Relatively little research has been done to determine how knowledge on CA-AKI prevention can be translated into clinical practice. Methods: We developed, implemented, and surveyed end-users about the usability, acceptability, and utility of an audit and feedback process for CA-AKI prevention in Alberta, Canada. The audit and feedback reported on amount of radiocontrast dye used, hemodynamic optimization of intravenous fluids, and CA-AKI incidence for each cardiologist practicing coronary angiography or percutaneous coronary intervention, compared with peers at their site and across the province. Reports were developed through an iterative process involving interventional cardiologists throughout the design process and usability testing. Results: Cardiologists participating in usability testing indicated a preference for the visual displays of data and summarizing indicators on the front page, and endorsed the value of peer-to-peer comparisons of performance measures. Of 31 eligible cardiologists from across Alberta, 17 responded to a survey evaluating the audit and feedback process. Fifteen respondents (88.2%) agreed that the data presented in the audit and feedback report were understandable; 17 respondents (100%) agreed or strongly agreed that the presentation of the report helped them better understand their performance compared with that of their peers; and 14 (82.4%) agreed that the audit and feedback process helped them identify ways to reduce the risk of AKI for their patients. Conclusions: Conducting an audit and providing feedback was an understandable and acceptable intervention to help cardiologists identify ways to improve prevention of CA-AKI during coronary angiography or intervention.


Contexte: L'insuffisance rénale aiguë provoquée par un produit de contraste (IRA-PC) est une complication possiblement évitable de la coronarographie et de l'intervention coronarienne. Relativement peu de travaux de recherche ont été menés pour déterminer comment les connaissances sur la prévention de l'IRA-PC peuvent se traduire dans la pratique clinique. Méthodologie: Nous avons élaboré et réalisé un sondage auprès d'utilisateurs finaux sur l'utilisabilité, l'acceptabilité et l'utilité d'un processus de vérification et de rétroaction pour la prévention de l'IRA-PC en Alberta, au Canada. Ce processus visait à rendre compte des données sur la quantité de substances de contraste utilisées, de l'optimisation hémodynamique des liquides intraveineux et de la fréquence de l'IRA-PC pour chaque cardiologue pratiquant des coronarographies ou des interventions coronariennes percutanées, comparativement à leurs confères du même centre et à ceux d'ailleurs dans la province. Les rapports ont été élaborés à l'aide d'un processus itératif auquel ont participé des cardiologues interventionnels tout au long du processus de conception et des tests d'utilisabilité. Résultats: Les cardiologues participant aux tests d'utilisabilité ont indiqué une préférence pour les affichages visuels des données et des indicateurs récapitulatifs sur la première page, et approuvé la valeur des comparaisons des mesures de rendement entre pairs. Sur les 31 cardiologues admissibles de partout en Alberta, 17 ont répondu au sondage évaluant le processus de vérification et de rétroaction. Quinze répondants (88,2 %) ont convenu que les données présentées dans le rapport de vérification et de rétroaction étaient compréhensibles; 17 répondants (100 %) étaient d'accord ou fortement d'accord que la présentation du rapport les avait aidés à mieux comprendre leur rendement comparativement à celui de leurs pairs; et 14 (82,4 %) ont convenu que le processus de vérification et de rétroaction les avait aidés à trouver des façons de réduire le risque d'IRA chez leurs patients. Conclusions: Procéder à une vérification et fournir une rétroaction s'est avérée une intervention compréhensible et acceptable pour aider les cardiologues à trouver des façons d'améliorer la prévention de l'IRA-PC pendant une coronarographie ou une intervention coronaire.

11.
Kidney Med ; 4(9): 100491, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-36046611

RESUMO

Rationale & Objective: Sick day medication guidance has been promoted to prevent adverse events for people with chronic conditions. Our aim was to summarize the existing sick day medication guidance and the evidence base for the effectiveness of interventions for implementing this guidance. Study Design: Scoping review of quantitative and qualitative studies. Setting & Population: Sick day medication guidance for people with chronic conditions including diabetes mellitus, kidney diseases, and cardiovascular diseases. Selection Criteria for Studies: A search of 6 bibliographic databases (Ovid MEDLINE, Ovid Embase, CINAHL, Scopus, Web of Science Core Collection, and Cochrane Library [via Wiley]) and a comprehensive gray literature search were completed in June 2021. Data Extraction: Intervention and study characteristics were extracted using standardized tools. Analytical Approach: Data were summarized descriptively, and our approach observed the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for scoping reviews. Results: The literature search identified 2,308 documents, which were screened against the eligibility criteria, leading to 74 documents that were included. The majority of the identified documents (n = 55) were guidelines or educational resources. Of the 19 primary research studies identified, 10 studies described an intervention, with only 2 examining the effect of sick day medication guidance interventions within clinical care and no studies reporting beneficial effects on clinical outcomes. Most documents (n = 58) included guidance specific to patients with diabetes mellitus, with fewer including guidance for patients with chronic kidney disease (n = 9) or heart failure (n = 2). Limitations: Risk of bias was not assessed. Conclusions: Many resources promoting sick day medication guidance have been developed; however, there is very little empirical evidence for the effectiveness of current approaches in implementing sick day medication guidance into practice. Recommendations for the use of sick day medication guidance will require further research to develop consistent, understandable, and usable approaches for its implementation within self-management strategies as well as empirical studies to demonstrate the effectiveness of these interventions.

12.
CJC Open ; 3(3): 337-344, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33778450

RESUMO

BACKGROUND: Acute kidney injury (AKI) after cardiac catheterization procedures is associated with poor health outcomes. We sought to characterize the experiences of patients after receiving standardized information on their risk of AKI accompanied by instructions for follow-up care after cardiac catheterization. METHODS: We implemented an initiative across 3 cardiac catheterization units in Alberta, Canada to provide standardized assessment, followed by guidance for patients at risk of AKI. This was accompanied by communication to primary care providers to improve continuity of care when patients transition from the hospital to the community. A structured survey from a sample of 100 participants at increased risk of AKI determined their perceptions of information provided and experiences with follow-up steps after the initiative was implemented in each cardiac catheterization unit in Alberta. RESULTS: The mean age of participants was 72.4 (SD 10.4) years, 37% were female, and the mean risk of AKI was 8.8%. Most (63%) participants were able to recall the information provided to them about their risk of kidney injury, 68% recalled the education provided on strategies to reduce risk, and 65% believed their primary care practitioner had received enough information to conduct appropriate follow-up care. Eighty-six percent of patients were satisfied with their transition to the community, and 53% were reassured by the information and follow-up care they received. CONCLUSIONS: These findings suggest that communicating risk information to patients, in combination with education and collaboration for follow-up with primary care providers, is associated with positive patient experiences and satisfaction with care.


CONTEXTE: L'insuffisance rénale aiguë (IRA) après un cathétérisme cardiaque est associée à de mauvais résultats en matière de santé. Nous avons voulu décrire l'expérience des patients après qu'on leur ait transmis de l'information standardisée concernant le risque d'IRA et des directives pour les soins de suivi après un cathétérisme cardiaque. MÉTHODOLOGIE: Nous avons mis en place une initiative dans trois unités de cathétérisme cardiaque en Alberta, au Canada, afin de permettre une évaluation standardisée, puis d'offrir des directives concernant les patients à risque d'IRA. Notre initiative comprenait également des communications aux fournisseurs de soins primaires en vue d'améliorer la continuité des soins prodigués aux patients quittant l'hôpital pour retourner en milieu communautaire. Un sondage structuré mené auprès de 100 participants présentant un risque accru d'IRA a permis de connaître leurs perceptions quant à l'information reçue et à leur expérience à l'égard du suivi après la mise en place de l'initiative dans chacune des unités de cathétérisme cardiaque en Alberta. RÉSULTATS: L'âge moyen des participants était de 72,4 ans (écart type : 10,4), 37 % étaient des femmes, et le risque moyen d'IRA était de 8,8 %. La plupart des participants (63 %) étaient en mesure de se souvenir de l'information qui leur avait été transmise au sujet de leur risque d'insuffisance rénale, 68 % se rappelaient la formation reçue concernant les stratégies pour réduire leur risque, et 65 % estimaient que leur médecin de soins primaires avait recueilli suffisamment d'information pour effectuer un suivi adéquat. Quatre-vingt-six pour cent (86 %) des patients étaient satisfaits de leur transition en milieu communautaire, et 53 % étaient rassurés par l'information reçue et le suivi dont ils faisaient l'objet. CONCLUSIONS: Ces résultats suggèrent que le fait de transmettre aux patients de l'information au sujet des risques, en plus de les éduquer et de leur permettre de collaborer avec leur fournisseur de soins primaires pour le suivi est associé à une expérience positive pour le patient et à la satisfaction à l'égard des soins reçus.

13.
Can J Kidney Health Dis ; 5: 2054358118763809, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29636981

RESUMO

BACKGROUND: The kidney failure risk equation (KFRE) provides an estimate of risk of progression to kidney failure, and may guide clinical care. OBJECTIVE: We aimed to describe patient, family, and health care provider's perspectives of the perceived benefits and challenges of using a risk-based approach to guide care delivery for patients with advanced chronic kidney disease (CKD), and refine implementation based on their input. METHODS: We used qualitative methodology to explore perceived benefits and challenges of implementing a risk-based approach (using the KFRE) to determine eligibility for multidisciplinary CKD care in Southern Alberta. We obtained perspectives from patients and families through focus groups, as well as input from health care providers through interviews and open-ended responses from an online survey. Twelve patients/family members participated in 2 focus groups, 16 health care providers participated in an interview, and 40 health care providers responded to the survey. RESULTS: Overall, participants felt that a KFRE-based approach had the potential to improve efficiency of the clinics by targeting care to patients at highest risk of kidney failure; however, they also expressed concerns about the impact of loss of services for lower risk individuals. Participants also articulated concerns about a perceived lack of capacity for adequate CKD patient care in the community. Our implementation strategy was modified as a result of participants' feedback. CONCLUSIONS: We identified benefits and challenges to implementation of a risk-based approach to guide care of patients with advanced CKD. Based on these results, our implementation strategy has been modified by removing the category of referral back to primary care alone, and instead having that decision made jointly by nephrologists and patients among low-risk patients.


CONTEXTE: La Kidney Failure Risk equation (KFRE), l'équation qui mesure le risque d'évolution vers la défaillance rénale, est susceptible d'orienter les soins prodigués en néphrologie. OBJECTIFS DE L'ÉTUDE: Nous souhaitions savoir comment les patients, leurs proches et leurs fournisseurs de soins percevaient le recours à une approche de prédiction du risque pour répartir les patients atteints d'insuffisance rénale chronique (IRC) dans le système de soins. Plus précisément, nous nous sommes intéressés aux avantages et aux défis perçus face à une telle approche, et les commentaires recueillis se destinaient à en raffiner la mise en œuvre. MÉTHODOLOGIE: Nous avons utilisé une méthodologie qualitative pour étudier les avantages et les défis perçus de la KFRE comme outil d'évaluation de l'admissibilité de patients sud-albertains atteints d'IRC à la prise en charge par une équipe multidisciplinaire. Les perceptions des patients et de leurs proches ont été recueillies lors de groupes de discussion; les fournisseurs de soins ont quant à eux donné leur avis au moyen d'entrevues et d'un sondage en ligne à questions ouvertes. Au total, douze patients et membres de leurs familles ont participé aux groupes de discussion, 16 fournisseurs des soins ont été interviewés et 40 ont répondu au sondage en ligne. RÉSULTATS: Dans l'ensemble, les participants étaient d'avis que la KFRE avait le potentiel d'améliorer l'efficience des cliniques en néphrologie en canalisant les soins vers les patients à risque élevé de défaillance rénale. Les participants se sont toutefois dits préoccupés par les éventuelles conséquences d'une perte de services pour les patients à moindre risque. Ils appréhendaient également une capacité insuffisante du milieu communautaire à prendre en charge les patients atteints d'IRC. Nous avons modifié notre stratégie de mise en œuvre suivant les commentaires recueillis. CONCLUSION: Cette étude nous a permis de recenser les avantages et les défis perçus face à l'application d'une approche fondée sur la KFRE pour prodiguer des soins aux patients atteints d'IRC à un stade avancé. À la lumière des résultats, la stratégie de mise en œuvre a été modifiée. Nous avons notamment supprimé la catégorie de renvoi automatique aux seuls soins primaires pour faire en sorte que, dans le cas de patients à faible risque, le mode de prise en charge soit conjointement déterminé par le néphrologue et le patient.

14.
Can J Kidney Health Dis ; 5: 2054358117753618, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29375884

RESUMO

BACKGROUND: Risk prediction tools are used in a variety of clinical settings to guide patient care, although their use in chronic kidney disease (CKD) care is limited. OBJECTIVES: To assess the association of a risk-based model of CKD care on patient care, satisfaction, outcomes, and cost. DESIGN: Mixed-methods with a pre-post design. SETTING: We will use mixed-methods and a pre-post design to evaluate use of the Kidney Failure Risk Equation (KFRE) to guide CKD care. The KFRE will be applied to patients currently followed in nephrology multidisciplinary CKD clinics in Alberta, as well as to new patients being considered for multidisciplinary care. PATIENTS: Patients with a 2-year risk of kidney failure ≥10% or estimated glomerular filtration rate (eGFR) ≤15 mL/min/1.73 m2 will be recommended care by a multidisciplinary team coordinated by a nurse clinician and nephrologist, with access to other multidisciplinary resources including dietitians, pharmacists, and social workers as required. MEASUREMENTS/METHODS: Focus groups and interviews will be conducted to qualitatively describe patient and provider perspectives of potential barriers and facilitators to implementation of the risk-based approach to CKD care. Patient and provider surveys will also be used to quantify patient and provider satisfaction before and after the intervention. Finally, administrative data will be used to evaluate the association between the risk-based approach to care and outcomes including health care resource use, frequency of testing, modality choice, and death. CONCLUSIONS: Use of a risk-based model of care has the potential to increase use of optimal treatments such as the use of home dialysis and preemptive kidney transplantation, while reducing costs and poor outcomes related to processes of care such as unnecessary laboratory testing; however, there is also potential for unintended consequences. Our mixed-methods approach will integrate perceptions and needs from key stakeholders (including patients with CKD, their families, and their providers) to guide implementation and ensure appropriate modifications.


CONTEXTE: Les outils de prévision des risques sont employés dans différents contextes cliniques pour orienter les soins prodigués aux patients. Néanmoins, leur usage dans le contexte de l'insuffisance rénale chronique (IRC) demeure limité. OBJECTIF: Évaluer, dans le contexte de l'IRC, l'influence qu'un modèle de soins intégrant la prévision des risques pourrait avoir sur les soins prodigués aux patients, sur leur satisfaction, sur l'évolution de la maladie et sur les coûts de santé. TYPE D'ÉTUDE: Méthode mixte avec évaluation avant et après l'intervention. CADRE DE L'ÉTUDE: À l'aide d'une méthode mixte et d'une évaluation avant et après l'intervention, nous mesurerons l'emploi de l'équation prédictive du risque d'évolution vers l'insuffisance rénale, la Kidney Failure Risk Equation (KFRE), comme guide de soins en IRC. La KFRE sera appliquée aux patients suivis actuellement dans les cliniques multidisciplinaires de néphrologie en Alberta, de même qu'à tous les nouveaux patients qui seront aiguillés vers les soins multidisciplinaires. PATIENTS: Deux groupes de patients seront aiguillés vers une équipe de soins multidisciplinaire coordonnée par une infirmière clinicienne et un néphrologue, soit les patients présentant un risque égal ou supérieur à 10 % de progresser vers l'insuffisance rénale d'ici deux ans, et ceux dont le débit de filtration glomérulaire estimé (DFGe) est de 15 ml/min/1,73 m2 ou moins. Ces patients auront également accès aux autres ressources de la clinique si nécessaire, notamment des nutritionnistes, des pharmaciens et des travailleurs sociaux. MÉTHODOLOGIE: Des groupes de discussion seront formés et des entretiens individuels seront menés pour sonder le point de vue des patients et des fournisseurs de soins sur les possibles obstacles et facilitateurs à l'adoption d'une approche de soins axée sur la prévision du risque. Ces sondages serviront également à évaluer la satisfaction des participants avant et après l'intervention. Les données administratives seront employées pour évaluer l'association entre une approche de soins axée sur la prévision du risque et les issues en lien avec l'intervention, notamment l'utilisation des ressources en santé, la fréquence des tests, le choix de modalité et le décès. CONCLUSION: L'emploi d'un modèle de soins intégrant la prévision du risque a le potentiel d'accroître le recours aux traitements optimaux tels que la dialyse à domicile et la greffe rénale préventive. Il permettra également de réduire les coûts de santé et les issues défavorables comme les tests de laboratoires inutiles. Par contre, ce modèle comporte aussi un risque de conséquences imprévues. Notre approche par méthodes mixtes intègrera les avis et les besoins des personnes impliquées (les patients atteints d'IRC, leurs familles et le personnel soignant) afin d'orienter la mise en œuvre et pour s'assurer d'apporter les modifications appropriées.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA